newsfilter
← Latest News
Business Wire·

TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor

-- Novel oral approach aimed at disrupting cancer metabolism in metastatic HR+/HER2- breast cancer – -- HR+/HER2- represents 73% of diagnoses and is the largest subtype of breast cancer1 – -- Breast cancer patients from prior first-in-human st